MYCN and neuroblastoma: Here, expression of TRPM2 was determined to be significantly higher in non-MYCN amplified neuroblastoma tumors compared to MYCN amplified tumors at all stages and specifically in Stage 4 disease, using three databases from the R2 platform (R2:Genomics Analysis and Visualization Platform; http://r2.amc.nl), chosen for analysis because of their high number of neuroblastoma samples (Fig. 1B, Supplementary Table 2)40,41.